MBX Biosciences, Inc. (MBX)
MBX moved a median of +0.07% 30 minutes after news, and -0.36% by the close. How MBX actually reacts to news — the realized, point-in-time move the market made, measured across 253 labeled events over the last three years with zero look-ahead.
MBX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.19% | 47% | 249 |
| 30-min | +0.07% | 52% | 252 |
| 60-min | -0.91% | 40% | 252 |
| to close | -0.36% | 49% | 249 |
| Middle 50% of MBX reactions | -1.08% to +2.58% |
|---|---|
| Median reaction (30-min) | +0.07% |
| Measured reactions | 253 |
Half of all MBX Biosciences, Inc. news events land between -1.08% and +2.58% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How MBX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | -0.19% | 50% | +0.50% |
| Coverage initiations | 42 | -1.76% | 31% | -1.29% |
| Rating reiterations | 22 | -1.00% | 41% | -2.78% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how MBX ranks against every other measured name →
That’s how MBX usually reacts — get an email when it moves on news →Email me when MBX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to MBX's baseline. Nothing else.
Recent MBX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| MBX Biosciences to Participate in Upcoming November Investor Conferences | Press release | GlobeNewswire | -0.07% | -5.84% | |
| MBX Biosciences to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.05% | -0.60% | |
| MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer | Press release | GlobeNewswire | +1.35% | +3.52% | |
| Form 8-K MBX Biosciences, Inc. For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | -0.86% | -0.51% | |
| MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Press release | GlobeNewswire | -0.86% | -0.51% | |
| Form 10-Q MBX Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.69% | +1.39% | |
| Form 8-K MBX Biosciences, Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.69% | +1.39% | |
| MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights | Press release | GlobeNewswire | +0.69% | +1.39% | |
| Attovia Therapeutics Appoints John W. Smither to Board of Directors | Press release | GlobeNewswire | -2.37% | +8.83% | |
| Form 8-K MBX Biosciences, Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | +0.28% | +7.14% | |
| MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth | Press release | GlobeNewswire | +0.28% | +7.14% | |
| Form 8-K MBX Biosciences, Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +3.52% | +10.97% | |
| MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism | Press release | GlobeNewswire | +3.52% | +10.97% | |
| Form 8-K MBX Biosciences, Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | -1.01% | |
| MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026 | Press release | GlobeNewswire | +2.17% | -2.23% | |
| MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City | Press release | GlobeNewswire | -2.17% | -1.46% | |
| Form 8-K MBX Biosciences, Inc. For: May 11 | SEC filing · Form 8-K | SEC EDGAR | +1.18% | -2.86% | |
| MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing | Press release | GlobeNewswire | +1.18% | -2.86% | |
| Form DEFA14A MBX Biosciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.18% | -2.86% | |
| Form 10-Q MBX Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.06% | +8.47% | |
| Form 8-K MBX Biosciences, Inc. For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -2.36% | +7.63% | |
| MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant Award | Press release | GlobeNewswire | -1.06% | +8.47% | |
| MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights | Press release | GlobeNewswire | -1.06% | +8.47% | |
| MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio | Press release | GlobeNewswire | -0.63% | -0.57% | |
| Form ARS MBX Biosciences, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.43% | +0.27% | |
| Form DEF 14A MBX Biosciences, Inc. For: Apr 22 | SEC filing · Form DEF | SEC EDGAR | -0.43% | +0.27% | |
| Form DEFA14A MBX Biosciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.43% | +0.27% | |
| MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.26% | -4.98% | |
| Form 10-K MBX Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.15% | -1.55% | |
| Form 8-K MBX Biosciences, Inc. For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | -2.15% | -1.55% | |
| Form S-3ASR MBX Biosciences, Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +4.24% | — | |
| Form S-8 MBX Biosciences, Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.15% | -1.55% | |
| MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights | Press release | GlobeNewswire | -2.15% | -1.55% | |
| MBX Biosciences Appoints Karen Basbaum as Chief Business Officer | Press release | GlobeNewswire | +2.14% | +3.61% | |
| CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism | Press release | GlobeNewswire | +0.78% | -5.22% | |
| Form 8-K MBX Biosciences, Inc. For: Mar 09 | SEC filing · Form 8-K | SEC EDGAR | +0.23% | -7.11% | |
| MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism | Press release | GlobeNewswire | +0.23% | -7.11% | |
| Form 8-K MBX Biosciences, Inc. For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +3.16% | -1.99% | |
| MBX Biosciences to Participate in Upcoming March Investor Conferences | Press release | GlobeNewswire | +2.95% | +4.76% | |
| MBX Biosciences to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -2.20% | -8.33% | |
| Form 8-K MBX Biosciences, Inc. For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | +2.67% | +2.45% | |
| Form 8-K MBX Biosciences, Inc. For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | -0.19% | +2.19% | |
| MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair | Press release | GlobeNewswire | -0.19% | +2.19% | |
| Form 8-K MBX Biosciences, Inc. For: Jan 11 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | +13.15% | |
| MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.64% | +13.15% | |
| MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 | Press release | GlobeNewswire | +0.50% | -5.40% | |
| Form EFFECT MBX Biosciences, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.39% | -7.96% | |
| MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference | Press release | GlobeNewswire | +0.95% | +3.94% | |
| Form 10-Q MBX Biosciences, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.09% | +9.81% | |
| Form 8-K MBX Biosciences, Inc. For: Oct 31 | SEC filing · Form 8-K | SEC EDGAR | +2.09% | +9.81% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the MBX section they belong to.
Where else MBX is measured.
MBX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is MBX Biosciences, Inc.'s median reaction calculated?
Every labeled MBX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 253 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of MBX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does MBX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.